vs
Business First Bancshares, Inc.（BFST）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Business First Bancshares, Inc.的1.5倍（$127.1M vs $83.1M），再鼎医药同比增速更快（17.1% vs 7.1%），Business First Bancshares, Inc.自由现金流更多（$92.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 16.8%）
第一公民银行股份公司是一家银行控股公司，总部位于美国北卡罗来纳州罗利，是美国规模最大的银行机构之一。公司核心子公司第一公民银行在全美23个州经营着超过500家网点，另一子公司硅谷银行则在15个州设有39家办事处。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
BFST vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$83.1M
营收增速更快
ZLAB
高出10.0%
7.1%
自由现金流更多
BFST
多$118.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
16.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.1M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 33.2% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 7.1% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.71 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFSTZLAB
| Q4 25 | $83.1M | $127.1M | ||
| Q3 25 | $80.9M | $115.4M | ||
| Q2 25 | $81.5M | $109.1M | ||
| Q1 25 | $79.2M | $105.7M | ||
| Q4 24 | $77.6M | $108.5M | ||
| Q3 24 | $66.9M | $101.8M | ||
| Q2 24 | $66.2M | $100.1M | ||
| Q1 24 | $60.9M | $87.1M |
净利润BFSTZLAB
| Q4 25 | — | — | ||
| Q3 25 | $22.9M | $-36.0M | ||
| Q2 25 | $22.1M | $-40.7M | ||
| Q1 25 | $20.5M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $17.8M | $-41.7M | ||
| Q2 24 | $17.2M | $-80.3M | ||
| Q1 24 | $13.6M | $-53.5M |
毛利率BFSTZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率BFSTZLAB
| Q4 25 | 33.2% | -54.6% | ||
| Q3 25 | 35.7% | -42.3% | ||
| Q2 25 | 34.4% | -50.3% | ||
| Q1 25 | 32.6% | -53.3% | ||
| Q4 24 | 27.5% | -62.6% | ||
| Q3 24 | 34.0% | -66.6% | ||
| Q2 24 | 32.9% | -76.0% | ||
| Q1 24 | 28.2% | -80.7% |
净利率BFSTZLAB
| Q4 25 | — | — | ||
| Q3 25 | 28.2% | -31.2% | ||
| Q2 25 | 27.1% | -37.3% | ||
| Q1 25 | 25.9% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 26.7% | -40.9% | ||
| Q2 24 | 26.0% | -80.2% | ||
| Q1 24 | 22.3% | -61.4% |
每股收益（稀释后）BFSTZLAB
| Q4 25 | $0.71 | $-0.05 | ||
| Q3 25 | $0.73 | $-0.03 | ||
| Q2 25 | $0.70 | $-0.04 | ||
| Q1 25 | $0.65 | $-0.04 | ||
| Q4 24 | $0.51 | $-0.09 | ||
| Q3 24 | $0.65 | $-0.04 | ||
| Q2 24 | $0.62 | $-0.08 | ||
| Q1 24 | $0.48 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $411.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $896.9M | $715.5M |
| 总资产 | $8.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BFSTZLAB
| Q4 25 | $411.2M | $689.6M | ||
| Q3 25 | $399.1M | $717.2M | ||
| Q2 25 | $495.8M | $732.2M | ||
| Q1 25 | $312.9M | $757.3M | ||
| Q4 24 | $319.1M | $779.7M | ||
| Q3 24 | $213.2M | $616.1M | ||
| Q2 24 | $208.1M | $630.0M | ||
| Q1 24 | $185.9M | $650.8M |
股东权益BFSTZLAB
| Q4 25 | $896.9M | $715.5M | ||
| Q3 25 | $878.4M | $759.9M | ||
| Q2 25 | $848.4M | $791.7M | ||
| Q1 25 | $826.3M | $810.8M | ||
| Q4 24 | $799.5M | $840.9M | ||
| Q3 24 | $699.5M | $667.7M | ||
| Q2 24 | $664.5M | $704.2M | ||
| Q1 24 | $649.0M | $762.2M |
总资产BFSTZLAB
| Q4 25 | $8.2B | $1.2B | ||
| Q3 25 | $8.0B | $1.2B | ||
| Q2 25 | $7.9B | $1.2B | ||
| Q1 25 | $7.8B | $1.2B | ||
| Q4 24 | $7.9B | $1.2B | ||
| Q3 24 | $6.9B | $985.3M | ||
| Q2 24 | $6.7B | $987.4M | ||
| Q1 24 | $6.7B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $92.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 110.7% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $165.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流BFSTZLAB
| Q4 25 | $92.1M | $-26.0M | ||
| Q3 25 | $32.4M | $-32.0M | ||
| Q2 25 | $14.0M | $-31.0M | ||
| Q1 25 | $28.7M | $-61.7M | ||
| Q4 24 | $61.4M | $-55.8M | ||
| Q3 24 | $21.4M | $-26.8M | ||
| Q2 24 | $15.1M | $-42.2M | ||
| Q1 24 | $7.6M | $-90.1M |
自由现金流BFSTZLAB
| Q4 25 | $92.0M | $-26.7M | ||
| Q3 25 | $32.1M | $-35.0M | ||
| Q2 25 | $13.8M | $-33.9M | ||
| Q1 25 | $27.7M | $-63.2M | ||
| Q4 24 | $59.8M | $-58.4M | ||
| Q3 24 | $21.0M | $-28.2M | ||
| Q2 24 | $14.0M | $-42.9M | ||
| Q1 24 | $7.2M | $-91.1M |
自由现金流率BFSTZLAB
| Q4 25 | 110.7% | -21.0% | ||
| Q3 25 | 39.6% | -30.4% | ||
| Q2 25 | 16.9% | -31.1% | ||
| Q1 25 | 34.9% | -59.9% | ||
| Q4 24 | 77.1% | -53.8% | ||
| Q3 24 | 31.4% | -27.7% | ||
| Q2 24 | 21.2% | -42.9% | ||
| Q1 24 | 11.8% | -104.5% |
资本支出强度BFSTZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 2.0% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 1.6% | 0.7% | ||
| Q1 24 | 0.6% | 1.1% |
现金转化率BFSTZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.56× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BFST
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
